Primary malignant melanoma of uterine cervix treated with pembrolizumab as adjuvant immunotherapy

We present our case to contribute its rarity of the disease case report, the primary MM of the uterine cervix that had poor response to pembrolizumab and had OS of 6  months. The treatment ineffectiveness is mainly considered for mucosal MM of low tumor mutation burden and its unusual type of pathology. Accumulation of retrospective studies exclusively on cervical melanoma needs to be proceeded to investigate on characteristics between poor and long survival to establish standardized treatment.
Source: International Cancer Conference Journal - Category: Cancer & Oncology Source Type: research